Oriola

1.17 EUR

-0.51 %

7,770 following

ORIOLA

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Investor consensus

-0.51 %

+1.74 %

+2.45 %

+3.17 %

+1.92 %

+25.54 %

-34.78 %

-42.93 %

-36.39 %

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

Market cap

216.83M EUR

Turnover

11.81K EUR

P/E (adj.) (25e)

27.9

EV/EBIT (adj.) (25e)

6.12

P/B (25e)

2.22

EV/S (25e)

0.08

Dividend yield-% (25e)

3.42 %

Coverage

Recommendation

Reduce

Target price

1.25 EUR

Updated

2026-01-14

Analyst

Latest research

Latest analysis report

Released: 2026-01-14

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

25/2

2026

Annual report '25

25/3

2026

General meeting '26

29/4

2026

Interim report Q1'26

Risk

Business risk

Valuation risk

Low

High

All

Research

Webcasts

Press releases

3rd party

ShowingAll content types

Oriola, Webcast, Q4'25

Webcast2/25/2026, 8:00 AM

Oriola, Webcast, Q4'25

Regulatory press release1/15/2026, 8:00 AM

Oriola Oyj: Proposals of the Shareholders' Nomination Board of Oriola Corporation concerning the Board of Directors to be elected by the 2026 Annual General Meeting

Oriola: Vi tror att balansräkningsarrangemangen närmar sig

Research1/14/2026, 6:00 AM by

Oriola: Vi tror att balansräkningsarrangemangen närmar sig

Vi tror att Oriola kommer att meddela planer på att sälja sitt ägande i Kronans Apotek och stärka företagets soliditet under vårens kapitalmarknadsdag.

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Oriola presenterade investeringsplanen för distributionscentret och belyste nyckelteman i den nya strategin

Analyst Comment1/8/2026, 6:34 AM by

Oriola presenterade investeringsplanen för distributionscentret och belyste nyckelteman i den nya strategin

Huvudsyftet med investeringen är att förbättra Oriolas produktivitet och säkerställa ytterligare kapacitet för framtida tillväxt.

Regulatory press release1/7/2026, 10:35 AM

Oriola Oyj: Inside information: Oriola accelerates growth and modernises Finnish operations with a highly automated, state-of-the-art distribution centre in Järvenpää

Press release1/7/2026, 10:30 AM

Oriola Oyj: Oriola initiates review of long-term plan, financial targets and capital allocation priorities - Capital Markets Day scheduled

Oriola: Nedskrivning av joint venture-bolaget Kronans värde, likt förra året

Analyst Comment12/19/2025, 11:25 AM by

Oriola: Nedskrivning av joint venture-bolaget Kronans värde, likt förra året

Nedskrivningen tynger Oriolas rapporterade resultat med 16 MEUR under resten av året, men påverkar inte kassaflödet eller justerade siffror.

Regulatory press release12/19/2025, 11:00 AM

Oriola Oyj: Kronans Apotek to record an impairment with an impact of approximately EUR 16 million to Oriola's net result

Press release12/15/2025, 11:00 AM

Oriola Oyj: Change negotiations in connection with Oriola's plan for a new distribution centre in Finland have been concluded

Oriola förbereder sig för att investera i ett nytt distributionscenter i Finland

Analyst Comment11/18/2025, 5:45 AM by

Oriola förbereder sig för att investera i ett nytt distributionscenter i Finland

Oriola meddelade igår att de inleder förhandlingar om nedskärningar med personalen vid hela Esbo-kontoret gällande byggandet av ett nytt distributionscenter i Järvenpää.

Press release11/17/2025, 7:00 AM

Oriola Oyj: Oriola initiates change negotiations in connection with plans for a new distribution centre in Finland

Third party research10/31/2025, 9:25 AM

Oriola: Earnings turning positive - Evli

Oriola posted good Q3 results, with a key positive the faster recovery than we had expected recovery of profitability in the Wholesale segment. With good development across the board, earnings also turned positive. We raise our target price to EUR 1....

Oriola Q3'25: Vi tror att vinsttillväxten fortsätter

Research10/31/2025, 5:30 AM by

Oriola Q3'25: Vi tror att vinsttillväxten fortsätter

Oriolas Q3-resultat var något bättre än våra förväntningar, och guidningen för vinsttillväxt upprepades som väntat.

Third party research10/30/2025, 9:05 AM

Oriola: Good development across the board - Evli

Oriola posted good figures in Q3. Net sales growth was nearly in the double-digits, while the adj. EBITDA of EUR 9.6m exceeded our EUR 9.1m expectations. Profitability was aided by faster than anticipated profitability recovery of the Wholesale-segment...

Oriola, Webcast, Q3'25

Webcast10/30/2025, 8:00 AM

Oriola, Webcast, Q3'25

Oriola Q3’25 snabbkommentar: Positiv utveckling både i den egna verksamheten och i joint venture-bolaget

Analyst Comment10/30/2025, 7:15 AM by

Oriola Q3’25 snabbkommentar: Positiv utveckling både i den egna verksamheten och i joint venture-bolaget

Oriolas vinst förbättrades något mer än våra förväntningar, både i dess egen verksamhet och i joint venture-bolaget Kronans. Guidningen för en förbättrad just. EBITDA för helåret upprepades som väntat.

Regulatory press release10/30/2025, 6:30 AM

Oriola Oyj: Oriola Corporation's Interim Report January-September 2025

Third party research10/28/2025, 8:46 AM

Oriola: Growth in place, profitability next - Evli

Oriola saw solid growth in Q2, and we anticipate a continued good growth pace in Q3. We expect the weaker profitability in the Wholesale-segment to improve gradually during the second half of the year, enabling y/y group level improvement.

Oriola Q3’25 förhandskommentar: Vi förväntar oss att vinsten växer

Analyst Comment10/28/2025, 5:00 AM by

Oriola Q3’25 förhandskommentar: Vi förväntar oss att vinsten växer

Oriola rapporterar sitt Q3-resultat torsdagen den 30 oktober cirka klockan 8.30. Vi förväntar oss att just. EBITDA förbättras något från jämförelseperioden, vilket därmed lyfter årets kumulativa resultat över jämförelseperioden.

Press release10/16/2025, 6:00 AM

Oriola Oyj: Oriola Corporation to publish its Interim Report for January-September 2025 on 30 October 2025

Forum discussions

This post is primarily intended for Oriola’s communications and finance departments as a comment for improving Oriola’s financial reporting and for the Capital Markets Day. The biggest problem with Oriola’s financial reporting is that true and fair information regarding the JV company...

1/19/2026, 2:10 PM

by Aktivisti26

15

The most sensible thing would be to freeze dividends completely for at least a couple of years. It’s idiotic to pay out dividends and then beg for the money back shortly after in a share issue. Naturally, via a directed issue at a discount, just to maximize the retail investors’ ...

1/14/2026, 3:15 PM

by tj_hodl

6

I already commented briefly on those thoughts from Aktivisten back in the autumn in this post. I still completely agree (as does @Makex above) that regarding Kronans’ valuation, Aktivisten is way off track. And since Oriola needs to strengthen its balance sheet due to a low equity...

1/14/2026, 7:16 AM

by Rauli_Juva

6

Hard to say, as it’s not very attractive in its current state (zero result and a very small share of e-commerce, where the market growth is). Our valuation for Oriola’s share is 75 MEUR. In my opinion, stating this “officially” and starting the process mainly creates an acute need...

1/14/2026, 1:23 PM

by Rauli_Juva

4

Selling Kronans Apotek would not remove the value from the balance sheet… It would change the asset to cash…

1/14/2026, 1:07 PM

by Fredrik

3

Okay, that’s clear. A dividend cut in itself doesn’t affect the company’s value, but of course, if it’s due to weakening free cash flow, then it’s a different story. There are indeed risks in Oriola, such as major development projects and the book value of the joint venture. But ...

1/14/2026, 7:21 AM

by tj_hodl

3

If they end up selling Kronans, its EV must be over 460m to avoid a loss for Oriola after the latest impairment. A sale below that value would also reduce equity. The problem lies in the high EVs used when the joint venture was established (9.2.2022): The enterprise value of Oriola...

1/14/2026, 4:55 PM

by Makex

2

Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.